ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

President Proposes $1 Billion Increase For NIH In FY2011; Cancer A High Priority

February 5, 2010

Vanderbilt Wins NCI Core Grant Renewal with 12.7 Percent Funding increase

December 3, 2010

NIEHS Uses Gene Chips To Evaluate Chemicals.

March 3, 2000

DRG Regulation Opponents May Have Powerful New Ally

November 25, 1983

Annual Report Finds Decreases In Overall Cancer Rates

December 11, 2009

Surveillance Colonoscopy Cost-Effective For High-Risk

July 30, 2010